Marjorie George, MD
Pulmonary Disease · Denver, CONPI 1457414203
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by United Therapeutics Corporation at 42.3% of the total. Reporting peaked in 2022 at $45,388 and has fallen 50.0% since, to $22,686 in 2025. Among pulmonary disease clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 251 payments — averaging $764.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$81K
- Actelion Pharmaceuticals US, Inc.$66K
- Bayer$21K
- Merck$17K
- Johnson & Johnson$6K
- Inari Medical, Inc.$215
- plus $357 from 6 others
Across 117 payments — averaging $3873.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$279K
- Janssen Research & Development, LLC$114K
- Actelion Pharmaceuticals, Ltd$60K
What the payments were for
- Consulting fees$59,81631%
- Speaking & faculty fees$108,65657%
- Travel & lodging$16,2598%
- Food & beverage$7,0954%
- Education$1350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 117 | $81,180 |
| Actelion Pharmaceuticals US, Inc. | 88 | $66,323 |
| Bayer | 20 | $20,977 |
| Merck | 13 | $16,937 |
| Johnson & Johnson | 6 | $5,970 |
| Inari Medical, Inc. | 1 | $215 |
| Boston Scientific | 1 | $175 |
| Insmed, Inc. | 1 | $97 |
| Sandoz | 1 | $27 |
| Liquidia Technologies, Inc. | 1 | $25 |
| GSK | 1 | $17 |
| Abbott | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$48,438
- OPSUMIT$43,258
- Adempas$20,727
- TYVASO$11,710
- NONE$6,077
- REMODULIN$2,452
- VELETRI$2,180
- WINREVAIR$1,371
- BOSENTAN$232
- FLOWTRIEVER CATHETER, S$215
- CT THROMBECTOMY SYSTEM KIT$215
- WATCHMAN Access System$175
- ORENITRAM$120
How this compares
$191,959 in reported general payments places this provider in the 95th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 381 | $4,825,568 |
| UptraviSelexipag | 111 | $2,707,233 |
| AdempasRiociguat | 148 | $2,095,660 |
| Tyvaso DpiTreprostinil | 60 | $1,382,161 |
| WinrevairSotatercept-Csrk | 31 | $438,071 |
| Ambrisentan | 112 | $370,430 |
| Orenitram ErTreprostinil Diolamine | 45 | $354,418 |
| LetairisAmbrisentan | 12 | $232,274 |
| Tadalafil | 340 | $220,050 |
| RemodulinTreprostinil Sodium | 12 | $215,501 |
| TracleerBosentan | 13 | $162,732 |
| Bosentan | 15 | $111,050 |
| EliquisApixaban | 57 | $60,371 |
| Sildenafil Citrate | 171 | $34,336 |
| XareltoRivaroxaban | 23 | $17,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Tracleer, Bosentan | $66,323 | $7,806,583520 claims |
| BayerAdempas | $20,977 | $2,095,660148 claims |
| MerckWinrevair | $16,937 | $438,07131 claims |
| United Therapeutics CorporationRemodulin | $81,180 | $215,50112 claims |
| Johnson & JohnsonXarelto | $5,970 | $17,11023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 pulmonary disease providers in Colorado.
Other pulmonary disease in Denver
- Michael WechslerDenver$2.7M
- Ronald BalkissoonDenver$1.2M
- Vamsi GunturDenver$310K
- Kevin BrownDenver$299K
- Rebecca KeithDenver$248K
- Everett SutherlandDenver$174K
- Charles DaleyDenver$166K
- Barry MakeDenver$162K
- Amy OlsonDenver$117K
- Robert SandhausDenver$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.